Antisense compounds, compositions and methods are provided for modulating the expression of PTPN12. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTPN12. Methods of using these compounds for modulation of PTPN12 expression and for treatment of diseases associated with expression of PTPN12 are provided.
Antisense modulation of transcription factor DP-1 expression
申请人:Isis Pharmaceuticals Inc.
公开号:US20030225012A1
公开(公告)日:2003-12-04
Antisense compounds, compositions and methods are provided for modulating the expression of transcription factor Dp-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding transcription factor Dp-1. Methods of using these compounds for modulation of transcription factor Dp-1 expression and for treatment of diseases associated with expression of transcription factor Dp-1 are provided.
Antisense compounds, compositions and methods are provided for modulating the expression of resistin. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding resistin. Methods of using these compounds for modulation of resistin expression and for treatment of diseases associated with expression of resistin are provided.
Antisense modulation of fatty acid synthase expression
申请人:——
公开号:US20040077570A1
公开(公告)日:2004-04-22
Antisense compounds, compositions and methods are provided for modulating the expression of fatty acid synthase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding fatty acid synthase. Methods of using these compounds for modulation of fatty acid synthase expression and for treatment of diseases associated with expression of fatty acid synthase are provided.
Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box O1A are provided, in particular, for methods of treating diabetes.